Broderick Brian C raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.3% during the second quarter, Holdings Channel reports. The fund owned 13,152 shares of the life sciences company’s stock after buying an additional 40 shares during the period. Broderick Brian C’s holdings in Illumina were worth $2,282,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Bank of Montreal Can boosted its position in shares of Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock worth $19,314,000 after buying an additional 42,876 shares in the last quarter. National Pension Service boosted its position in shares of Illumina by 3.7% in the first quarter. National Pension Service now owns 122,352 shares of the life sciences company’s stock worth $21,186,000 after buying an additional 4,331 shares in the last quarter. Gulf International Bank UK Ltd boosted its position in shares of Illumina by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,040 shares of the life sciences company’s stock worth $7,685,000 after buying an additional 600 shares in the last quarter. Forte Capital LLC ADV boosted its position in shares of Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. boosted its position in shares of Illumina by 33.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 346,451 shares of the life sciences company’s stock worth $59,114,000 after buying an additional 85,922 shares in the last quarter. 93.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Illumina, Inc. (ILMN) traded down 0.40% on Monday, hitting $172.06. 309,764 shares of the stock were exchanged. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $189.48. The stock’s 50-day moving average is $175.68 and its 200-day moving average is $170.24. The stock has a market cap of $25.12 billion, a price-to-earnings ratio of 34.82 and a beta of 0.84.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The business had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. During the same quarter last year, the company posted $0.71 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. Analysts forecast that Illumina, Inc. will post $3.63 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Broderick Brian C Acquires 40 Shares of Illumina, Inc. (ILMN)” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/07/24/broderick-brian-c-acquires-40-shares-of-illumina-inc-ilmn.html.

ILMN has been the topic of a number of recent analyst reports. Piper Jaffray Companies reissued an “overweight” rating and set a $187.00 price target (up from $170.00) on shares of Illumina in a research report on Friday, April 14th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target on the stock in a research report on Tuesday, April 4th. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $188.84 price target on the stock. in a research report on Monday, March 27th. Cantor Fitzgerald lifted their price target on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 26th. Finally, Leerink Swann reissued a “buy” rating on shares of Illumina in a research report on Wednesday, April 5th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $166.54.

In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the transaction, the director now owns 534,176 shares in the company, valued at $91,221,235.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total transaction of $3,682,800.00. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at approximately $99,283,868.64. The disclosure for this sale can be found here. Insiders have sold 125,248 shares of company stock valued at $22,281,673 in the last 90 days. 1.60% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.